Actinium Pharmaceuticals, Inc.
ATNM
$9.80
-$0.05-0.51%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 81.00K | 81.00K | 0.00 | 45.00K | 90.00K |
| Total Revenue | 81.00K | 81.00K | 0.00 | 45.00K | 90.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 81.00K | 81.00K | 0.00 | 45.00K | 90.00K |
| SG&A Expenses | 12.56M | 13.33M | 14.98M | 15.33M | 14.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.01M | 52.00M | 52.87M | 48.36M | 40.61M |
| Operating Income | -49.93M | -51.92M | -52.87M | -48.32M | -40.52M |
| Income Before Tax | -46.45M | -48.82M | -50.14M | -46.34M | -38.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.45 | -48.82 | -50.14 | -46.34 | -38.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.45M | -48.82M | -50.14M | -46.34M | -38.93M |
| EBIT | -49.93M | -51.92M | -52.87M | -48.32M | -40.52M |
| EBITDA | -49.26M | -51.28M | -52.23M | -47.65M | -39.89M |
| EPS Basic | -1.72 | -1.84 | -1.92 | -1.80 | -1.55 |
| Normalized Basic EPS | -1.08 | -1.15 | -1.20 | -1.13 | -0.97 |
| EPS Diluted | -1.72 | -1.84 | -1.92 | -1.81 | -1.56 |
| Normalized Diluted EPS | -1.08 | -1.15 | -1.20 | -1.13 | -0.97 |
| Average Basic Shares Outstanding | 108.59M | 106.40M | 104.47M | 102.57M | 100.09M |
| Average Diluted Shares Outstanding | 108.59M | 106.40M | 104.47M | 102.57M | 100.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
